文献速递白血病造血干细胞移植与细胞治疗

急性髓系白血病第二次完全缓解期异基因造血干细胞移植:EBMT注册组报告

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.
PubMed 文献 · Leukemia · 2019-07-30

该注册组研究纳入1879例年龄≥18岁、2007-2016年首次接受allo-HCT的AML CR2患者,其中1010例(54%)接受MAC。在<50岁患者中MAC与RIC的2年LFS、OS、NRM和GRFS相当;在≥50岁患者中LFS、OS和GRFS相当,但MAC的NRM显著更高(27% vs 19%,P=0.01)。

要点

  • <50岁AML CR2患者MAC与RIC移植2年LFS均为54%,OS分别为61%与62%。
  • ≥50岁患者MAC与RIC的2年LFS为52% vs 49%,OS为58% vs 55%。
  • ≥50岁患者MAC的2年NRM显著高于RIC(27% vs 19%,P=0.01)。

核心结论

  • 在AML CR2患者中,<50岁时MAC与RIC移植2年结局相当;≥50岁时MAC的NRM显著更高。

研究设计与样本

  • EBMT急性白血病工作组注册组研究,纳入1879例年龄≥18岁、2007-2016年首次allo-HCT、诊断时细胞遗传学可用的AML CR2患者。
  • 供者类型包括匹配家族供者、HLA 10/10或9/10抗原匹配的志愿无关供者或单倍体相合供者。
  • 1010例(54%)接受MAC allo-HCT。

主要发现

  • <50岁患者MAC vs RIC的2年LFS均为54%,OS为61% vs 62%,NRM为18% vs 15%,GRFS为38% vs 42%。
  • ≥50岁患者MAC vs RIC的2年LFS为52% vs 49%,OS为58% vs 55%,GRFS为42.4% vs 36%。
  • ≥50岁患者MAC的2年NRM显著更高(27% vs 19%,P=0.01),尽管RIC后cGVHD更差(32% vs 39%)。

临床怎么用

  • 对于<50岁AML CR2患者,MAC与RIC移植的2年结局相当,可个体化选择预处理强度。
  • 对于≥50岁AML CR2患者,选择MAC需权衡其显著更高的NRM。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Transplantation Registry studied an AML CR2 cohort characterised by age ≥ 18 years, first allo-HCT 2007-2016, available cytogenetic profile at diagnosis, donors who were matched family, volunteer unrelated with HLA antigen match 10/10 or 9/10 or haplo-identical. The 1879 eligible patients included 1010 (54%) MAC allo-HCT recipients. In patients <50 years (y), two year outcomes for MAC vs RIC allo-HCT were equivalent with leukaemia-free survival (LFS) 54% for each, overall survival (OS), 61% vs 62%, non-relapse mortality (NRM) 18% vs 15% and graft versus host disease relapse-free survival (GRFS) 38% vs 42%. In patients ≥50 y, 2 y outcomes for MAC vs RIC allo-HCT were equivalent for LFS 52% vs 49%, OS 58% vs 55% and GRFS 42.4% vs 36%. However, NRM was significantly inferior after MAC allo-HCT, 27% vs 19% (P = 0.01) despite worse cGVHD after RIC-allo (32% vs 39%). These data support the need for ongoing prospective study of conditioning intensity and GVHD mitigation in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gilleece MH, Labopin M, Savani BN, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2019. PMID: 31363160. doi:10.1038/s41375-019-0527-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。